Trial Profile

A Phase 1/2 trial assessing EXS73565 in in B-cell malignancies, including CLL

Status: Planning

Phase of Trial: Phase I/II

Latest Information Update: 05 Mar 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs REC 3565 (Primary)
Indications B-cell lymphoma; Chronic lymphocytic leukaemia
Focus Adverse reactions; Therapeutic Use
Acronyms EXCELERIZE

Most Recent Events

28 Feb 2025 According to an Recursion Pharmaceuticals media release, the company has received CTA approval for REC-3565 (MALT1 inhibitor) in b-cell malignancies.
07 Jan 2025 According to an Recursion Pharmaceuticals media release, the first patient is expected to be dosed in the Phase 1 EXCELERIZE clinical trial in Q1 2025.
20 Nov 2024 According to an Recursion Pharmaceuticals media release, Exscientia is acquired by Recursion Pharmaceuticals.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com